VativoRx, LLC

05/12/2026

FDA approved Ponlimsi™ (denosumab-adet), another biosimilar to Prolia® for osteoporosis and bone loss conditions. More competition in this space means more access and cost pressure on the reference drug.

https://vativorx.com/pharmacy-bulletin-05-12-2026/

On March 30, 2026, the US Food and Drug Administration (FDA) approved Teva Pharmaceutical Industries’ Ponlimsi™ (denosumab-adet), another biosimilar to Prolia® (denosumab).

05/08/2026

FDA approved Opdivo® as a first-line treatment for advanced Hodgkin lymphoma, a major shift from its prior use in relapsed disease. Trial data showed a 58% reduction in risk of progression or death vs. the previous standard.

https://vativorx.com/pharmacy-bulletin-05-08-2026/

On March 20, 2026, the US Food and Drug Administration (FDA) approved Bristol Myers Squibb’s Opdivo® (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of previously untreated stage III or IV classical Hodgkin lymphoma in adult and pediatric patients...

05/06/2026

FDA approved Avlayah™ for Hunter syndrome, a rare pediatric disease with ~500 US patients. It's the first therapy to cross the blood-brain barrier and treat neurologic symptoms. Est. annual cost: $270K.

https://vativorx.com/pharmacy-bulletin-05-06-2026/

On March 24, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics’ Avlayah™ (tividenofusp alfa-eknm) for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or sympto...

05/04/2026

FDA approved Lifyorli™ for platinum-resistant ovarian cancer — a first-in-class oral drug that helps chemo work better by blocking cortisol-driven resistance. Approved 2.5 months ahead of schedule.

https://vativorx.com/pharmacy-bulletin-05-04-2026/

On March 25, 2026, the US Food and Drug Administration (FDA) approved Corcept Therapeutics’ Lifyorli™ (relacorilant) in combination with nab‑paclitaxel for the treatment of adult patients with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have receiv...

04/30/2026

PSG just released their 2026 Trends in Specialty Drug Benefits Report, and one number stands out.

93% of surveyed organizations receive specialty drug rebates under the pharmacy benefit. Only 51% receive them under the medical benefit.

That 42-point gap has a story behind it. New edition of The Rebate Report breaks it down. 👇

📋 https://www.linkedin.com/pulse/specialty-drug-rebate-gap-now-measurable-numbers-significant-ac07e

04/28/2026

The FDA just expanded approval of Cosentyx® (secukinumab) to teens aged 12+ for hidradenitis suppurativa (HS) — a painful, chronic skin condition that often starts around puberty. Previously adult-only, this marks Cosentyx's 4th pediatric indication.

https://vativorx.com/pharmacy-bulletin-04-28-2026/

On March 13, 2026, the US Food and Drug Administration (FDA) approved Novartis’ Cosentyx® (secukinumab) injection for the treatment of moderate to severe hidradenitis suppurativa (HS) in pediatric patients aged 12 years and older. Previously, it was only approved for adults who had this chronic i...

04/22/2026

🧴 FDA approves Icotyde™, a new once-daily oral pill for moderate-to-severe psoriasis in patients 12+.

It’s the first drug of its kind to target the IL-23 receptor and showed strong results in helping patients achieve clearer skin.

https://vativorx.com/pharmacy-bulletin-04-22-2026/

On March 18, 2026, the US Food and Drug Administration (FDA) approved Johnson & Johnson and Protagonist Therapeutics’ Icotyde™ (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis (PsO) in adults and pediatric patients aged 12 years and older weighing at least 40kg who are cand...

04/21/2026

🧠 FDA approves Pylarify TruVu™, a next-gen imaging agent for prostate cancer detection.

This updated version improves supply and access while helping doctors more effectively detect cancer spread or recurrence. Launch expected late 2026.

https://vativorx.com/pharmacy-bulletin-04-21-2026/

On March 6, 2026, the US Food and Drug Administration (FDA) approved Lantheus Holdings’ Pylarify TruVu™ (piflufolastat F 18) injection for positron emission tomography (PET) imaging of prostate‑specific membrane antigen (PSMA)–positive lesions in men with prostate cancer who have suspected m...

04/17/2026

The White House signed a tariff proclamation on patented pharmaceuticals earlier this month. The rates are still taking shape as manufacturers negotiate deals, but the underlying cost management question it raises is worth thinking through now.

New edition of The Rebate Report breaks it down. 👇

https://www.linkedin.com/pulse/what-pharma-tariff-environment-reveals-specialty-drug-cost-aetce

On April 2nd, the White House signed a proclamation imposing new tariffs on patented pharmaceutical products and their active pharmaceutical ingredients under Section 232 of the Trade Expansion Act of 1962, the same national security trade authority that underlies longstanding tariffs on steel and a

04/13/2026

🚨 FDA expands Palynziq® approval to include adolescents 12+ with PKU. This enzyme therapy helps lower harmful phenylalanine levels and offers a new option beyond diet alone.



Read more:

On Feb. 27, 2026, the US Food and Drug Administration (FDA) approved BioMarin Pharmaceutical’s Palynziq® (pegvaliase‑pqpz) for use in adolescents aged 12 years and older with phenylketonuria (PKU).

04/09/2026

🚨 FDA approves Yuviwel® for children ages 2+ with achondroplasia whose growth plates are still open. This once-weekly injection is designed to help improve linear growth and offers a new treatment option for families managing this rare condition.



Read more:

On Feb. 27, 2026, the US Food and Drug Administration (FDA) approved Ascendis Pharma’s Yuviwel® (navepegritide) for the treatment of children aged two years and older with achondroplasia who have open epiphyses, meaning their bone growth plates have not yet closed.